ID: hyp-SDA-2026-04-09-gap-debate-20260409-2
Hypothesis
Lectin-Mediated Autophagy Enhancers
Small molecule enhancers of endogenous lectins (like galectin-3) could specifically recognize altered glycan patterns on tau vesicles and direct them toward autophagosomal degradation.
EvidencePending (0%)📖 5 cit🗣 1 debates✓ 5 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Small molecule enhancers of endogenous lectins (like galectin-3) could specifically recognize altered glycan patterns on tau vesicles and direct them toward autophagosomal degradation. This would create a selective clearance pathway for pathological tau aggregates.
🧬 Mechanism
🔗 Mechanism from KG for LGALS3
Auto-built from this analysis's top knowledge-graph edges.
graph TD
LGALS3["LGALS3"] -->|regulates| autophagy["autophagy"]
LGALS3_1["LGALS3"] -->|targets| tau_vesicles["tau_vesicles"]
LGALS3_2["LGALS3"] -->|modulates| autophagy_pathway["autophagy_pathway"]
LGALS3_3["LGALS3"] -->|enhances| autophagy_4["autophagy"]
style LGALS3 fill:#ce93d8,stroke:#333,color:#000
style autophagy fill:#4fc3f7,stroke:#333,color:#000
style LGALS3_1 fill:#4fc3f7,stroke:#333,color:#000
style tau_vesicles fill:#4fc3f7,stroke:#333,color:#000
style LGALS3_2 fill:#4fc3f7,stroke:#333,color:#000
style autophagy_pathway fill:#81c784,stroke:#333,color:#000
style LGALS3_3 fill:#ce93d8,stroke:#333,color:#000
style autophagy_4 fill:#81c784,stroke:#333,color:#000⚖️ Evidence
⚖️ Evidence Matrix5 supports3 contradicts
Supports
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Supports
Trehalose induces autophagy via lysosomal-mediated TFEB activation in models of motoneuron degeneration.
Supports
Neuroanatomical Quantitative Proteomics Reveals Common Pathogenic Biological Routes between Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD).
Supports
VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle.
Supports
Microglial transcriptome analysis in the rNLS8 mouse model of TDP-43 proteinopathy reveals discrete expression profiles associated with neurodegenerative progression and recovery.
Contradicts
Organelle-specific autophagy in inflammatory diseases: a potential therapeutic target underlying the quality control of multiple organelles.
Contradicts
Mesenchymal Stem Cell-Derived Exosomes as New Remedy for the Treatment of Neurocognitive Disorders.
Contradicts
Wallerian degeneration: the innate-immune response to traumatic nerve injury.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — LGALS3
No curated PDB or AlphaFold mapping for LGALS3 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for LGALS3.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.0535
Events (7d)
0
Price History
▲6.0%💾 Resource Usage
LLM Tokens
14,284
$0.0857
Total Cost
$0.0857
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF the carbohydrate recognition domain (CRD) of galectin-3 is required for tau clearance, THEN a CRD-mutant galectin-3 (R186S, critical for glycan binding) will fail to reduce pathological tau levels | Wild-type galectin-3 overexpression produces >35% reduction in tau aggregates; CRD-mutant produces <15% reduction (no different from empty vector) | — no observation — | pending | 0.35 |
| IF galectin-3 (LGALS3) is pharmacologically enhanced via small molecule activators or viral overexpression in primary neurons seeded with pathological tau aggregates, THEN phosphorylated tau (p-tau Se | At least 40% reduction in Sarkosyl-insoluble phosphorylated tau (Ser396, AT8-positive) measured by ELISA or immunoblot | — no observation — | pending | 0.45 |
🔮 Falsifiable Predictions (2)
pendingconf 45%
IF galectin-3 (LGALS3) is pharmacologically enhanced via small molecule activators or viral overexpression in primary neurons seeded with pathological tau aggregates, THEN phosphorylated tau (p-tau Ser396) levels will decrease by at least 40% relative to vehicle controls within 48-72 hours of treatm
Predicted outcome: At least 40% reduction in Sarkosyl-insoluble phosphorylated tau (Ser396, AT8-positive) measured by ELISA or immunoblot
Falsification: No significant reduction in pathological tau levels (<15% change) or equivalent reduction in total tau and non-target proteins, indicating non-selective general autophagy induction rather than lectin-
pendingconf 35%
IF the carbohydrate recognition domain (CRD) of galectin-3 is required for tau clearance, THEN a CRD-mutant galectin-3 (R186S, critical for glycan binding) will fail to reduce pathological tau levels when overexpressed, while wild-type galectin-3 will reduce tau, in matched neuronal cultures within
Predicted outcome: Wild-type galectin-3 overexpression produces >35% reduction in tau aggregates; CRD-mutant produces <15% reduction (no different from empty vector)
Falsification: CRD-mutant galectin-3 produces equivalent tau reduction to wild-type, disproving the necessity of carbohydrate recognition domain for tau clearance and indicating a non-specific scaffolding function
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesis
| source | v1_phase_c_backfill |
| origin_type | debate_synthesis |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.